Heart failure (HF) represents a burgeoning global health crisis, with its profound impact on the quality of life and mortality rates becoming increasingly evident. This impact is particularly stark within the aging population, where the prevalence of heart failure continues to rise. The intricate nature of heart failure arises from numerous interwoven biological pathways. These pathways are often exacerbated by the physiological changes associated with aging.
Fig. 1 Schematic of processes and pathways contributing to age-related cardiac disease. (Li H, et al., 2020)
CD BioSciences specializes in drug discovery services that target age-related pathways to develop effective therapeutics for heart failure. Our comprehensive approach combines various technologies with extensive research expertise to accelerate the development of cardiac anti-aging drugs.
How Do We Discover Cardiac Anti-Aging Drugs Targeting Age-Related Pathways?
Drug discovery targeting cardiomyocyte senescence in heart failure
Cardiomyocyte senescence, the process of aging at the cellular level within the heart muscle, contributes to the progression of heart failure. CD BioSciences supports clients in developing senolytics targeting cardiomyocyte senescence, potentially restoring cardiac function and improving heart health. Our experts offer analysis services to determine the effects of senolytics on the aged heart in animal models.
Drug discovery targeting vascular senescence in heart failure
Aging leads to structural and functional changes in blood vessels. Our research services aim to help clients develop vasodilatory agents that enhance vascular function and reduce afterload. We focus on developing novel drugs that enhance endothelial function, promote vascular health, and reduce the risk of heart failure.
Drug discovery targeting inflammaging in heart failure
We offer drug discovery services to identify anti-inflammatory agents that mitigate the effects of cytokines in senescent cells, which effectively disrupt the cycle of inflammation and senescence in heart failure.
Drug discovery targeting mitochondrial dysfunction in heart failure
Mitochondrial dysfunction as a hallmark of aging is closely linked to the development of heart failure. We help clients identify and develop promising therapeutic agents targeting mitochondrial dysfunction for heart failure treatment. Our research services focus on discovering drugs that can enhance mitochondrial function and bioenergetics.
Our Integrated Approaches for Cardiac Anti-Aging Drug Discovery
CD BioSciences offers comprehensive cardiac anti-aging drug discovery services through an integrated multi-platform approach, combining advanced technologies with a deep understanding of the disease's complexities.
Identification and validation of aging-related genes in heart failure
We use an integrated drug discovery platform that combines high-throughput screening, computational modeling, and in-depth biological expertise to identify aging-related genes in heart failure. We also help clients validate each target thoroughly in relevant preclinical models, providing a foundation for drug development.
Preclinical modeling and evaluation services
Our preclinical modeling expertise enables clients to assess the efficacy and safety of drug candidates in aging-related heart failure models. We also help clients conduct detailed pharmacokinetic and pharmacodynamic studies to optimize the therapeutic index of drug candidates.
The complexity of heart failure, particularly as it relates to aging-related pathways, necessitates a focused approach to drug discovery. CD BioSciences is committed to accelerating the discovery of cardiac anti-aging drugs targeting heart failure pathways. If you are interested in our services, please feel free to contact us or make an online inquiry.
Reference
- Li H, et al. Targeting Age-Related Pathways in Heart Failure. Circ Res, 2020, 126 (4): 533-551.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
